Merck buys into microarray market
Merck KGaA buys ProteoPlex in a move designed to shore up its
position in the emerging microarray market, estimated to reach $2
billion (€1.76bn) in 2008.
Genetix lifted by new orders
Shares in the UK's Genetix rose 15 per cent yesterday after the
company, which makes gene and protein research equipment, said it
had received orders from leading pharmaceutical groups for two of
its new products.
Serum stripper aids in biomarker discovery
Agilent launches two new products at the ongoing Drug Discovery
Technology meeting, including an LC column to remove high-abundance
proteins from serum and an oligonucleotide mouse microarray to aid
in toxicogenomics research.
Evotec stands firm in tough environment
Evotec OAI has posted a strong set of figures in the first half of
2003 as operating losses are trimmed by a third and EBITDA enters
USA speeds generic approvals
The pharmaceutical industry is facing the possibility of earlier
generic competition for its branded products from 18 August, when
new legislation in the USA comes into effect.
Forget cloning, try sloning
Sloning BioTechnology is to receive grants totalling more than €1
million to help it commercialise new technologies in
fully-automated gene synthesis.
Marketing meets R&D
A new report looks at how early-stage pharmaceutical marketing can
reduce the attrition in drug development by uniting R&D and
EuropaBio names keynote speakers
The organisers of CORDIA EuropaBio 2003 have revealed the keynote
speakers for the 'largest convention in Europe for trade,
investment, partnership and information exchange'.
Caliper sheds jobs after Zymark buy
Caliper has cut 9 per cent of its staff as part of a restructuring
exercise following its $72 million acquisition of lab automation
Scancell, Celltech team up on new cancer target
Scancell and Celltech are to collaborate on the development of
novel monoclonal antibody therapeutics targeting Lewis y/b, a new
LION sells compound library to Norak
LION bioscience of Germany has sold a compound library consisting
of more than 500,000 diverse compounds to US company Norak
High throughput ion channel screening
Swedish biotech tools company Cellectricon says it has now received
orders from three of the top five pharmaceutical companies for its
Dynaflow microfluidic chip technology for increasing productivity
in the drug discovery process.
HIV vaccine trial raises hopes of developing world
The first vaccine targeting the strains of HIV prevalent in
sub-Saharan Africa and Asia, where millions of people are infected
with the virus, has started Phase I volunteer studies in the USA.
Researchers unravel LacY web
An Anglo-US team of researchers has unveiled the first structure of
a membrane transport protein; disruptions in the activity of MTPs
are involved in a number of diseases.
Roche takes crystal-clear route to development
Swiss drugmaker Roche has succeeded in developing a crystalline
form of one of its pipeline compounds with the help of a US
company, TransForm Pharmaceuticals, that is applying a
high-throughput approach to form and formulation.
LIT spectrometer pushes back sensitivity barrier
A linear ion trap (LIT) spectrometer that is up to 10 times more
sensitive than current systems will be launched later this year by
Applied Biosystems/MDS SCIEX
Qiagen sales accelerate on new product lines
Qiagen has reported strong growth in sales and profits in the
second quarter as last year's acquisitions of GenoVision and
Xeragon start to exert their effects. The company has also signed
two new deals in the area of RNA interference.
Angiogenesis conference set for September
A conference examining the progress made in the field of
angiogenesis inhibition,organised by SRI, will take place 29-30
September in Cambridge, Massachusetts.
Pharmagene says profitability is a realistic objective
Pharmagene has reported a near-doubling in turnover in the first
half of this year, on the back of strong growth in its drug
discovery services division.
Dharmacon gets US RNAi patent
Dharmacon has been awarded a US Patent (No 6,590,093) which covers
its proprietary 2'-ACE chemistry for the production of synthetic
Takeda strikes deals to boost pipeline
Takeda signs two new research collaborations in the areas of
Alzheimer's disease and antibody-based drugs, in a move to bolster
its product pipeline.
GPC says anti-MHC antibody is nearing clinic
GPC reports progress with its anti-MHC class II antibody, with
potential in a range of haematological malignancies, and says it
now has sufficient quantities to start a clinical trials programme.
Pfizer pulls out of Phytopharm collaboration
Botanical drug specialist Phytopharm suffered a setback yesterday
when Pfizer withdrew from a collaboration to develop P57, a drug
for obesity and metabolic syndrome.
Gene silencing promise sparks IP rush
The battle to amass intellectual property in the hot area of RNA
interference (RNAi) continues to gain pace, with one of the key
players in the category, Alnylam Pharmaceuticals, licensing patents
from the UK's Cambridge Research...
siRNA library to benefit Abbott, and others
Dharmacon and Abbott Laboratories are to develop a
short-interfering RNA (siRNA) library covering 4,000 genes to help
identify potential drug targets.
Argonaut exits HPLC business
Argonaut sells its HPLC business to Grace Vydac as it refocuses on
supplying consumables for companies working on drug discovery.
Reports reduced losses in first half.
New skin cancer gene located
Cancer Research UK scientists have found the location of a new gene
on chromosome 1 which pre-disposes people to skin cancer.
GSK signs up for ACLARA's eTag system
GSK is the latest company to sign a license for ACLARA Biosciences'
eTag Assay System, used in gene expression profiling studies.
Speeding up the search for natural medicines
German researchers have developed a technique to speed up the
discovery of medicinal plant compounds, using a combination of
three analysis techniques.
Roche buys its way out of diagnostics trouble
Roche has moved to settle its long-running legal dispute with
USA-based Igen by acquiring the firm in a deal valued at around
$1.4 billion (€1.22bn).
Amersham trims 2003 profit forecast again
Amersham trimmed its 2003 profit forecast by £40 million (€57m), or
4.1 pence per share, after reporting lower sales and pre-tax
profits for the first half of 2003.
CYP450 variant licensed for genotyping
EPIDAUROS Biotechnologie has acquired a non-exclusive licence for
the diagnostic use of one of the most important genetic variants of
the cytochrome P450 2D6 gene.
EU raps states on animal protection
The European Commission sends written warnings to France, Belgium
and the Netherlands for failing to comply with its regulations on
ASINEX gets new contract from J&J
Russia's ASINEX extends its discovery chemistry contract with
J&J for an additional 12-month period; also launches three
targeted compound libraries.
Bio-Rad buoyed by 2Q figures
Bio-Rad Laboratories defies the often-reported turndown in the life
sciences supply industry with a healthy hike in second quarter
sales and profits.
InnaPhase completes Beckman LAO buy
InnaPhase has completed the transaction of Beckman Coulter's
Laboratory Automation Operations (LAO) that was announced in May of
Tecan takes comfort from stronger second quarter
Tecan second-quarter results reveal some signs of recovery after a
torrid first quarter and the departure of former chief executive
Emile Sutcliffe, with diagnostics holding back an improved
performance in biopharma.
Roche in talks to buy Igen?
Roche is said to be considering a purchase of diagnostics company
Igen International after a US appeals court ruling put a slice of
the Swiss group's diagnostics operations in jeopardy.
Genome on a chip from Applied Bio
Applied Biosystems has unveiled a gene expression analysis product
that allows researchers to conduct studies on the entire human
genome using a single microarray.
Novel psychiatric drugs licensed by Abiogen
Italy's Abiogen Pharma has licensed rights to two UK-developed
compounds that seem to work via a completely new mechanism of
action for the treatment of anxiety.
Pharma's focus on growth "unsustainable" says report
The pharmaceutical industry is failing to increase efficiencies in
core areas of its business - such as clinical trials and sales -
because of an enormous pressure from investors to drive revenues,
according to Datamonitor.
PIERIS expands IP in Anticalins
PIERIS has strengthened its patent estate for a new class of
proteins which could represent a more flexible alternative to
Drug delivers double-whammy to diabetes
Scientists at Roche have discovered a new class of drug, called
glucokinase activators, that may be of use in the treatment of
patients with type 2 diabetes.
Amersham alliance on image analysis
Amersham Biosciences and Geneva Bioinformatics have hooked up to
provide a new version of the ImageMaster package used in 2-D gel
Enanta develops new ketolide class
Enanta has discovered a type of macrolide that could represent a
new class of antibiotic for the treatment of upper and lower
respiratory tract infections.
Towards the transcriptome - without arrays
The market for non-array products used in the analysis of the
transcriptome - a map of gene expression and mRNA in the cell - is
maturing quickly but will still grow at more than 14 per cent a
year between 2003 and 2008, says a report...
Millipore 2Q sales up but biotech static
Millipore has reported buoyant sales growth in the second quarter
of this year but was let down by a lacklustre showing from its
biotechnology division, held up as one of the key drivers of future
Therascope raises €24m for drug discovery
Therascope, a privately held biopharmaceutical company focused on
small molecule drug discovery, has raised €24.1 million to develop
its TACE platform.
Tecan links with EMD for proteomics tools
Switzerland's Tecan has forged a co-marketing alliance with EMD
Biosciences in the area of automated systems for medium- to
high-throughput protein extraction, screening and purification. The
collaboration will focus on companies...
First CYP450 structure published
Astex Technology has published the first three-dimensional study of
a human cytochrome P450 protein involved in drug metabolism in the